Printer Friendly

Uroplasty, Inc. CEO Daniel Holman Talks to The Wall Street Transcript.

NEW YORK--(BUSINESS WIRE)--April 27, 1999--

The Wall Street Transcript has published an in-depth interview with Daniel G. Holman of Uroplasty, Inc. (OTC BB:UROP), in which he talks at length about his company's future.

He says, "Uroplasty was incorporated in 1992 as a urological medical device manufacturer. I took over the company in 1992 and brought it through reorganization. We came out of Chapter 11 in early 1994 and then restructured our overseas organization, consisting of manufacturing, sales, and marketing. We ended up with a separate company called Uroplasty. Uroplasty's main product is Macroplastique (R), which is an injectable soft tissue bulking material for the treatment of stress urinary incontinence."

He explains, "Macroplastique is designed to treat stress incontinence. It's a very, very large market - billions of dollars worldwide. Coming out of Chapter 11, we had limited resources in both capital and personnel. We elected to pursue Europe and other markets outside of the United States and to focus our limited resources on obtaining a CE Mark for Macroplastique and its necessary components in Europe. We raised capital last year through a private placement which netted about $3.3-$3.4 million. That money is earmarked for the regulatory process in the United States, which we are beginning now."

Looking forward, he states, "Although Macroplastique is not currently available in the U.S., its future in this market will be significant. An IDE (Investigational Device Exemption) submission to the U.S. Food and Drug Administration to begin U.S. clinical trials with Macroplastique is expected in 1999. The growth potential is very strong and, of course, the U.S. will be the largest market for us. We currently have very good growth in the European market."

To read the complete interview, go to http://www.twst.com/ceos.htm. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 35 years. The Transcript publishes industry roundtables and interviews with Wall Street analysts, money managers, and Company CEOs, and is read by top money managers, brokers, and individual investors. For subscription information call (800) 246 -7673.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 27, 1999
Words:371
Previous Article:The Wall Street Transcript publishes Education Stocks Issue.
Next Article:Local/Regional ISPs are Deploying VPNs, DSL, and VoIP.


Related Articles
Tanknology-NDE International CEO A. Daniel Sharplin talks to The Wall Street Transcript.
United States Basketball League CEO Daniel Meisenheimer, III talks to The Wall Street Transcript.
Bradley Pharmaceuticals CEO Daniel Glassman talks to The Wall Street Transcript.
RMH Teleservices, Inc. CFO Noah Asher Talks to The Wall Street Transcript.
Frisby Technologies, Inc. CEO Greg Frisby Talks to The Wall Street Transcript.
Network Appliance's CEO Daniel Warmenhoven talks to The Wall Street Transcript.
VCampus' CEO Daniel Neal Talks to The Wall Street Transcript.
Intrawest's Chief Financial Officer Daniel Jarvis talks to The Wall Street Transcript.
The Wall Street Transcript Publishes CEO Interview with James Keyes of Johnson Controls in Deutsche Banc Alex. Brown 2000 Basic Industries Conference...
The Wall Street Transcript Publishes CEO Interview with Daniel Somers of AT&T Broadband in Credit Suisse First Boston Media Conference issue.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters